Concepedia

Publication | Open Access

Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease

DOIFull Paper Access

26

Citations

24

References

2011

Year

Cesar Homero Gutiérrez‐Aguirre, Olga Graciela Cantú‐Rodríguez, Omar D. Borjas‐Almaguer, Óscar González‐Llano, J.C. Jaime-Pérez, Manuel Solano-Genesta, Miguel Ángel Gómez‐Guijosa, Consuelo Mancías‐Guerra, Luz Tarin, D. Gomez-Almaguer
Haematologica

Abstract

This combination therapy appears to be an efficacious and safe treatment for steroid-refractory chronic graft-versus-host disease. Longer follow up to determine the durability of response and survival is required (ClinicalTrials.gov: NCT01042509).

References

YearCitations

Page 1